Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Yongdong Jin et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39
<p>Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma</p>Dafeng Xu, Jinfang Zheng|OncoTargets and Therapy|2020Cited by 17
Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK PathwayJuncheng Guo, Jinfang Zheng|Cancer Management and Research|2021Cited by 11